First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta

In this analysis, we describe population-based outcomes for first-line treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) combined with an aromatase inhibitor (AI). All patients who were prescribed CDK4/6i + AI from January 2016 through June 2019 were included. Patient demographics, tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Amaro, Carla P., Batra, Atul, Lupichuk, Sasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293123/
https://www.ncbi.nlm.nih.gov/pubmed/34207443
http://dx.doi.org/10.3390/curroncol28030209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293123/
https://www.ncbi.nlm.nih.gov/pubmed/34207443
http://dx.doi.org/10.3390/curroncol28030209

Ejemplares similares